Read More

Anemia Advantage For GSK’s Blood Cancer Therapy Could Influence Market Share Despite Incyte’s Jakafi Comparison

Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythaemia), in 

BMY

Read More

European Authority Gives Thumbs Down To PTC Therapeutics’ Duchenne Therapy; Analyst Says It Can Overturn The Challenge

Friday morning, the Committee for Medicinal Products for Human Use of the European Medicines Agency gave a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of PTC Therapeutics Inc's (NASDAQ: PTCT) Translarna (ataluren) for nonsense m

PTCT

Read More

Apple Taps Seasoned Executive To Head ‘Secret’ Team Developing Glucose Monitoring Device – Stocks To Watch

Apple Inc (NASDAQ: AAPL) has appointed Tim Millet, a seasoned executive with a background in iPhone and Mac chip technology, to oversee its secretive team dedicated to developing a noninvasive blood sugar monitor, signaling a significant move in the company's health technology endeavors. 

AAPL